The Supreme Court is set to review whether generic drug maker Hikma can be held liable for patent infringement when pharmacists substitute its product for Amarin's patented Vascepa, despite the FDA approving only non-patented uses. This case impacts how generics are marketed and dispensed, potentially affecting pharmaceutical competition and patient access to cheaper drugs. The outcome could set a precedent on the liability threshold for generic manufacturers under secondary liability laws.
Read the full article at SCOTUSblog
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.
2
alinemati1983-6987Written by alinemati1983-6987
